Compare BAND & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | HELP |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.6M | 366.7M |
| IPO Year | 2017 | N/A |
| Metric | BAND | HELP |
|---|---|---|
| Price | $15.58 | $8.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $20.40 | ★ $95.00 |
| AVG Volume (30 Days) | 428.8K | ★ 579.8K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $204,113,000.00 | N/A |
| Revenue This Year | $17.15 | N/A |
| Revenue Next Year | $7.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $11.33 | $5.76 |
| 52 Week High | $18.63 | $8.23 |
| Indicator | BAND | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 64.44 |
| Support Level | $15.02 | $7.33 |
| Resistance Level | $16.64 | $8.23 |
| Average True Range (ATR) | 0.96 | 0.61 |
| MACD | 0.25 | 0.17 |
| Stochastic Oscillator | 76.59 | 98.06 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.